methylprednisolone has been researched along with Candidemia in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 1 (100.00) | 2.80 |
Authors | Studies |
---|---|
Ball, L; Bassetti, M; Battaglini, D; Brunetti, I; Bruzzone, B; Codda, G; Crea, F; De Maria, A; Dentone, C; Di Biagio, A; Giacobbe, DR; Icardi, G; Magnasco, L; Marchese, A; Mikulska, M; Orsi, A; Patroniti, N; Pelosi, P; Robba, C; Signori, A; Taramasso, L; Vena, A | 1 |
1 other study(ies) available for methylprednisolone and Candidemia
Article | Year |
---|---|
Bloodstream infections in critically ill patients with COVID-19.
Topics: Aged; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Bacteremia; Betacoronavirus; Candidemia; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Critical Illness; Cross Infection; Enterobacter aerogenes; Enterobacteriaceae Infections; Enterococcus faecalis; Enterococcus faecium; Female; Gram-Positive Bacterial Infections; Humans; Incidence; Intensive Care Units; Italy; Male; Methylprednisolone; Middle Aged; Pandemics; Pneumococcal Infections; Pneumonia, Viral; Proportional Hazards Models; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Risk Factors; SARS-CoV-2; Staphylococcal Infections; Staphylococcus aureus; Streptococcus pneumoniae | 2020 |